Prostate Cancer P D:经历前列腺活检男性的直肠穹窿氟喹诺酮抗性细菌预测因子研究

2018-10-15 AlexYang MedSci原创

氟喹诺酮(FQ)抗性直肠穹窿菌群与经历经直肠超声引导的前列腺穿刺活检(TRUS-PNB)的男性的感染性并发症相关。最近,有研究人员确定了能够预测FQ抗性直肠培养物的患者因素,这些患者经历了直肠超声引导的前列腺穿刺活检。研究发现,在分析的6179个直肠拭子中,4842(78%)名为FQ敏感性,1337名(22%)为FQ抗性。在单变量分析中,年龄的增加、优先TRUS-PNB、获得的更高的活检核心数目、

氟喹诺酮(FQ)抗性直肠穹窿菌群与经历经直肠超声引导的前列腺穿刺活检(TRUS-PNB)的男性的感染性并发症相关。最近,有研究人员确定了能够预测FQ抗性直肠培养物的患者因素,这些患者经历了直肠超声引导的前列腺穿刺活检。

研究发现,在分析的6179个直肠拭子中,4842(78%)名为FQ敏感性,1337名(22%)为FQ抗性。在单变量分析中,年龄的增加、优先TRUS-PNB、获得的更高的活检核心数目、糖尿病和过去6个月内抗菌剂使用和非白种人均是FQ抗性的预测因子(所有P<0.05)。那些具有FQ抗性的男性更可能具有TRUS-PNB良性病变(P=0.004)。在多变量分析中,患者年龄的增加(OR=1.01/年 [1.00-1.02])、过去6个月内抗菌剂的使用(OR=2.85[2.18-3.72])、非裔美国人(OR=1.99 [1.66-2.37])、亚洲人(OR=3.39 [2.63-4.37])和西班牙(OR=2.10 [1.72-2.55])种族均与FQ抗性直肠培养物独立相关。另外,总的感染比例为1.1%(56/5214),脓毒症率为0.46%(24/5214)。在FQ抗性组中,感染率为3.9%(43/1107);而FQ敏感组为0.3%(13/4107)(P<0.001)。

最后,研究人员指出,年龄的增加、抗菌剂的使用和非白种人是FQ抗性的独立预测因子。由于FQ抗性与感染的并发症相关,理解潜在的风险因子有助于感染控制的探索。

原始出处:

Wei Phin Tan, Dimitri Papagiannopoulos, Kalyan C Latchamsetty et al. Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy. Prostate Cancer P D. 02 Oct 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1928446, encodeId=fb321928446ce, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 22 07:39:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046036, encodeId=41db204603695, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sat Sep 28 08:39:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791550, encodeId=edca1e9155038, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jun 18 17:39:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665963, encodeId=3f4e16659634c, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Oct 31 08:39:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349827, encodeId=854b34982ed6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 19 11:01:37 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278110, encodeId=ae4712e81105e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310701, encodeId=75d91310e0150, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364401, encodeId=bd531364401d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523104, encodeId=9b5f15231048d, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602065, encodeId=01f71602065c0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1928446, encodeId=fb321928446ce, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 22 07:39:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046036, encodeId=41db204603695, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sat Sep 28 08:39:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791550, encodeId=edca1e9155038, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jun 18 17:39:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665963, encodeId=3f4e16659634c, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Oct 31 08:39:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349827, encodeId=854b34982ed6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 19 11:01:37 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278110, encodeId=ae4712e81105e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310701, encodeId=75d91310e0150, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364401, encodeId=bd531364401d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523104, encodeId=9b5f15231048d, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602065, encodeId=01f71602065c0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1928446, encodeId=fb321928446ce, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 22 07:39:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046036, encodeId=41db204603695, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sat Sep 28 08:39:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791550, encodeId=edca1e9155038, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jun 18 17:39:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665963, encodeId=3f4e16659634c, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Oct 31 08:39:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349827, encodeId=854b34982ed6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 19 11:01:37 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278110, encodeId=ae4712e81105e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310701, encodeId=75d91310e0150, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364401, encodeId=bd531364401d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523104, encodeId=9b5f15231048d, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602065, encodeId=01f71602065c0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1928446, encodeId=fb321928446ce, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 22 07:39:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046036, encodeId=41db204603695, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sat Sep 28 08:39:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791550, encodeId=edca1e9155038, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jun 18 17:39:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665963, encodeId=3f4e16659634c, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Oct 31 08:39:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349827, encodeId=854b34982ed6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 19 11:01:37 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278110, encodeId=ae4712e81105e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310701, encodeId=75d91310e0150, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364401, encodeId=bd531364401d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523104, encodeId=9b5f15231048d, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602065, encodeId=01f71602065c0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2018-10-31 yige2012
  5. [GetPortalCommentsPageByObjectIdResponse(id=1928446, encodeId=fb321928446ce, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 22 07:39:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046036, encodeId=41db204603695, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sat Sep 28 08:39:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791550, encodeId=edca1e9155038, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jun 18 17:39:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665963, encodeId=3f4e16659634c, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Oct 31 08:39:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349827, encodeId=854b34982ed6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 19 11:01:37 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278110, encodeId=ae4712e81105e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310701, encodeId=75d91310e0150, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364401, encodeId=bd531364401d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523104, encodeId=9b5f15231048d, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602065, encodeId=01f71602065c0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2018-10-19 一个字-牛

    学习了谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1928446, encodeId=fb321928446ce, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 22 07:39:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046036, encodeId=41db204603695, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sat Sep 28 08:39:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791550, encodeId=edca1e9155038, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jun 18 17:39:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665963, encodeId=3f4e16659634c, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Oct 31 08:39:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349827, encodeId=854b34982ed6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 19 11:01:37 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278110, encodeId=ae4712e81105e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310701, encodeId=75d91310e0150, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364401, encodeId=bd531364401d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523104, encodeId=9b5f15231048d, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602065, encodeId=01f71602065c0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1928446, encodeId=fb321928446ce, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 22 07:39:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046036, encodeId=41db204603695, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sat Sep 28 08:39:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791550, encodeId=edca1e9155038, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jun 18 17:39:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665963, encodeId=3f4e16659634c, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Oct 31 08:39:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349827, encodeId=854b34982ed6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 19 11:01:37 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278110, encodeId=ae4712e81105e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310701, encodeId=75d91310e0150, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364401, encodeId=bd531364401d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523104, encodeId=9b5f15231048d, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602065, encodeId=01f71602065c0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1928446, encodeId=fb321928446ce, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 22 07:39:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046036, encodeId=41db204603695, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sat Sep 28 08:39:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791550, encodeId=edca1e9155038, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jun 18 17:39:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665963, encodeId=3f4e16659634c, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Oct 31 08:39:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349827, encodeId=854b34982ed6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 19 11:01:37 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278110, encodeId=ae4712e81105e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310701, encodeId=75d91310e0150, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364401, encodeId=bd531364401d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523104, encodeId=9b5f15231048d, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602065, encodeId=01f71602065c0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2018-10-17 lsndxfj
  9. [GetPortalCommentsPageByObjectIdResponse(id=1928446, encodeId=fb321928446ce, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 22 07:39:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046036, encodeId=41db204603695, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sat Sep 28 08:39:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791550, encodeId=edca1e9155038, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jun 18 17:39:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665963, encodeId=3f4e16659634c, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Oct 31 08:39:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349827, encodeId=854b34982ed6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 19 11:01:37 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278110, encodeId=ae4712e81105e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310701, encodeId=75d91310e0150, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364401, encodeId=bd531364401d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523104, encodeId=9b5f15231048d, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602065, encodeId=01f71602065c0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1928446, encodeId=fb321928446ce, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 22 07:39:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046036, encodeId=41db204603695, content=<a href='/topic/show?id=e5713251390' target=_blank style='color:#2F92EE;'>#前列腺活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32513, encryptionId=e5713251390, topicName=前列腺活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ba8129, createdName=zhzhxiang, createdTime=Sat Sep 28 08:39:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791550, encodeId=edca1e9155038, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jun 18 17:39:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665963, encodeId=3f4e16659634c, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Wed Oct 31 08:39:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349827, encodeId=854b34982ed6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Oct 19 11:01:37 CST 2018, time=2018-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278110, encodeId=ae4712e81105e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310701, encodeId=75d91310e0150, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364401, encodeId=bd531364401d8, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523104, encodeId=9b5f15231048d, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602065, encodeId=01f71602065c0, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Oct 17 04:39:00 CST 2018, time=2018-10-17, status=1, ipAttribution=)]
    2018-10-17 sunylz

相关资讯

Sci Rep:不同格林森评分前列腺癌中类固醇激素受体和基质细胞标记表达比较

抗血管生成和免疫调节药物最近的发展表明了肿瘤微环境(TME)在癌症研究中越来越重要。最近,有研究人员通过比较不同GS组中类固醇激素受体的组织表达情况、癌症激活成纤维细胞(CAF)标记和血管密度情况,调查了格林森评分(GS)与TME之间的相关性。匹配的患者群体组成了不同的GS分组(6-7-8)。研究人员利用6个样本/患者的组织芯片进行免疫组化染色。研究人员对染色的片子进行数字化,并对基质和上皮进行选

Oncogene:肌醇聚磷酸酯4-磷酸酶II型调控雄激素受体的活性

晚期前列腺癌中AR的激活和转录重组总是与2个肿瘤抑制因子,INPP4B和PTEN的功能丧失同时发生,上述2个肿瘤抑制因子在人类和小鼠前列腺上皮中高表达。虽然AR信号通过PTEN的调控已经被多个研究组阐释,但是否INPP4B功能的丧失影响AR的活性仍旧不清楚。最近,有研究人员利用前列腺癌细胞系,展示了INPP4B能够调控AR转录活性和致瘤信号途径Akt和PKC。在前列腺癌患者群体中基因表达的分析表明

Prostate Cancer P D:约翰·霍普金斯积极监控群体PTEN状态评估

格林森评分6(GS6)前列腺癌男性中,那些最初通过积极监控(AS)来进行治疗的多达一半的患者都需要确定性的治疗,通常是由于跟踪调查期间肿瘤等级的重新界定。最近,有研究人员调查了患有GS6癌症且进行AS的男性患者,活检时的PTEN状态和随后的临床病理结果。研究人员在约翰·霍普金斯AS群体中进行了案例-对照研究,这些患者诊断的活检组织可以用于免疫组化(IHC)染色,并在所有的患者中,利用遗传学确定的方

Lancet oncol:激素疗法的顺序和放射照射的面积对前列腺癌患者预后的影响

NRG/RTOG 9413研究显示,与仅对前列腺进行放射治疗(PORT)联合新辅助激素治疗(NHT)、全骨盆放疗(WPRT)联合辅助激素治疗(AHT)和PORT联合AHT相比,WPRT联合NHT可提高中高风险的局限性前列腺癌患者的无进展存活率。现Prof Mack Roach等人对激素疗法的顺序和放射照射的面积对前列腺癌患者预后的影响进行研究。研究人员设计了一个2x2的阶乘研究,以激素治疗顺序和放

Sci Rep:包含活性基质前列腺癌组织的代谢和转录组分析

活性基质是一种组织特性,通常在前列腺癌的肿瘤微环境中观察到,并且与恶性肿瘤相关。最近,有研究人员在完全相同的前列腺癌组织样本中,检测了活性氧基质包含物中差异表达的基因和代谢物质。研究人员利用组织病理学评估了来自43名前列腺切除术后患者的108份冷冻的前列腺癌样本活性氧基质。研究人员在部分样本中利用高分辨率魔角旋转磁共振光谱(HR-MAS MRS)he RNA芯片分别分析了代谢物(n=85)和转录组

Oncogene:PDZ结合激酶和雄激素受体相互反馈能够驱使前列腺癌发生

阐释雄激素受体(AR)活性增加和随后恶性前列腺癌(PrCa)发展的潜在的机制在发展新的理论方面是非常关键的。最近,有研究人员利用系统生物学的方法,分析了AR调控的蛋白组,并坚定了一个新的AR调控的蛋白-PDZ结合激酶(PBK),该蛋白能够在PrCa中调节全程AR和AR变异体的活性。PBK在恶性PrCa中的过表达与早期生化复发和不良临床结果相关。除了碳末端配体结合区域,PBK还可以与AR的氮末端反式